Courtney Marabella

The latest findings for the PARP inhibitor in prostate cancer come from an analysis of the pivotal phase 3 PROfound trial presented during the 2021 AUA Annual Meeting.

The results come from a posthoc analysis of the pivotal phase 3 ARCHES trial.

Adding N-803 to Bacille Calmette-Guérin achieved a complete response in nearly three-fourths of patients with BCG-unresponsive, non-muscle invasive bladder cancer.

Papillary renal cell carcinoma (RCC) is a rare malignancy, accounting for 15% of all RCC cases.

“To reduce the incidence of metastatic prostate cancer in the United States, we support policies that promote shared decision making to optimize PSA screening," said Vidit Sharma, MD.